

substituted carbocyclalkynyl, optionally substituted aryl, or optionally substituted heteroaryl;

Y is optionally substituted alkyl, optionally substituted cycloalkylalkyl, heterocyclalkyl or aralkyl; and

Z is an optionally substituted group chosen from *N*-heterocycl, -O-heterocyclalkyl, -N(H)-heterocyclalkyl, or -N(Me)-heterocyclalkyl.

[0005] One embodiment provides a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0006] One embodiment provides a method of regulating gene transcription in a cell comprising inhibiting lysine-specific demethylase 1 activity by exposing the lysine-specific demethylase 1 enzyme to a compound of Formula (I).

[0007] One embodiment provides a method of treating cancer in a patient in need thereof, comprising administering to the patient a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

[0007a] One embodiment provides the use of a compound of Formula (I), wherein Y is optionally substituted alkyl, optionally substituted aralkyl, cycloalkylalkyl, or heterocyclalkyl; X is H, optionally substituted aryl, or optionally substituted heteroaryl; W1 is CH, CF or N; W2 is CH or CF; Z is optionally substituted *N*-heterocycl, -N(H)-heterocyclalkyl, or -O-heterocyclalkyl; and A is N or CH, in the manufacture of a medicament for regulating gene transcription in a cell by inhibiting lysine-specific demethylase 1 for treating acute myeloid leukemia or breast cancer.

[0007b] One embodiment provides the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating acute myeloid leukemia or breast cancer in a patient in need thereof.

INCORPORATION BY REFERENCE

[0008] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

DETAILED DESCRIPTION OF THE INVENTION

[0009] As used herein and in the appended claims, the singular forms "a," "and," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "an agent" includes a plurality of such agents, and reference to "the

26. The compound or pharmaceutically acceptable salt of claims 1-25, wherein Y is optionally substituted cycloalkylalkyl.
27. The compound or pharmaceutically acceptable salt of claims 1-25, wherein Y is optionally substituted alkyl.
28. The compound or pharmaceutically acceptable salt of claims 1-25, wherein Y is optionally substituted heterocyclalkyl.
29. The compound or pharmaceutically acceptable salt of claims 1-25, wherein Y is optionally substituted aralkyl.
30. The compound or pharmaceutically acceptable salt of claim 27, wherein the optionally substituted alkyl is an optionally substituted C₁-C₃ alkyl.
31. The compound or pharmaceutically acceptable salt of claim 27, wherein the optionally substituted alkyl is an optionally substituted C₁ alkyl.
32. The compound or pharmaceutically acceptable salt of claim 27, wherein the optionally substituted alkyl is a methyl group.
33. The compound or pharmaceutically acceptable salt of any of the preceding claims, wherein A is N.
34. The compound or pharmaceutically acceptable salt of any one of claims 1-32, wherein A is C-R.
35. The compound or pharmaceutically acceptable salt of any one of claims 1-32, wherein A is C-R, and R is hydrogen
36. The compound or pharmaceutically acceptable salt of any one of claims 1-32, wherein A is C-R and R is optionally substituted alkyl.
37. A pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
38. Use of a compound of Formula (I), wherein Y is optionally substituted alkyl, optionally substituted aralkyl, cycloalkylalkyl, or heterocyclalkyl; X is H, optionally substituted aryl, or optionally substituted heteroaryl; W¹ is CH, CF or N; W² is CH or CF; Z is optionally substituted N-heterocycl, -N(H)-heterocyclalkyl, or -O-heterocyclalkyl; and A is N or CH, in the manufacture of a medicament for regulating gene transcription in a cell by inhibiting lysine-specific demethylase 1 for treating acute myeloid leukemia or breast cancer.
39. Use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating acute myeloid leukemia or breast cancer in a patient in need thereof.